Tissue Regenix Group PLC - Leeds, England-based medical device company - Reports revenue of $24.5 million for 2022, up 24% from $19.7 million a year earlier. Particularly, BioRinse increased by 26% to $16.0 million from $12.7 million. Pretax loss narrows to $2.8 million from $5.1 million in 2021, as operating loss narrows to $2.0 million from $4.4 million. Declares no dividend for the year, unchanged from a year prior. Looking ahead, Tissue Regenix says it is well prepared for additional market fluctuations as markets continue to normalise post-pandemic.
Chair Jonathan Glenn says: ‘During what has been a year of immense progress with some notable milestones achieved, we have continued to demonstrate and realise operational and commercial growth.’
Current stock price: 0.61 pence each, up 0.5% on Tuesday around noon in London
12-month change: up 56%
Copyright 2023 Alliance News Ltd. All Rights Reserved.
